Eli Lilly Korea announced on July 1 that Seiya Komatsu has been appointed as the new CEO of Eli Lilly Korea.


Seiya Komatsu, the new CEO of Eli Lilly Korea, is a global business leader who joined Eli Lilly and Company (Lilly) headquarters as a recruiter and has since accumulated diverse experience in sales, marketing, business innovation, and organizational operations in both Japan and the United States.

Seiya Komatsu, new CEO of Lilly Korea. Lilly Korea

Seiya Komatsu, new CEO of Lilly Korea. Lilly Korea

View original image

After earning his MBA from Brigham Young University in the United States, Seiya Komatsu began his career in sales for the Diabetes Business Unit at Eli Lilly Japan. He later worked in business innovation at the global headquarters and served as branch manager for the Texas region in the U.S. Since 2020, he has overseen brand marketing for the incretin portfolio at Eli Lilly Japan, and immediately prior to his appointment as CEO of Eli Lilly Korea, he served as Executive Vice President and Head of the Neuroscience Business Unit at Eli Lilly Japan.


In his remarks upon taking office, Seiya Komatsu stated, "It is an honor to lead Eli Lilly Korea in this meaningful year, marking the 150th anniversary of Eli Lilly and Company. Korea is a core strategic market for Lilly, equipped with world-class bio-infrastructure and excellent research talent. I will do my utmost to ensure the rapid introduction of innovative new drugs and to improve treatment accessibility for patients in Korea." He added, "I will serve as a bridge connecting Lilly's global network with Korea's bio-pharmaceutical capabilities, carrying forward Lilly's 150-year legacy of patient-centered innovation and care here in Korea."



Eli Lilly Korea is currently contributing to the advancement of healthcare in Korea by supplying innovative treatments and conducting clinical research in various therapeutic areas, including cardiovascular and metabolic diseases, neurodegenerative diseases, oncology, and immunology. Recently, the company signed a USD 500 million investment agreement with the Ministry of Health and Welfare and is working to establish the Lilly Gateway Labs (LGL) hub in Songdo, Incheon, further strengthening its collaboration with Korea's bio-innovation ecosystem.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing